City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation

Border Border
The following is a list of available studies directed by  Margaret O'Donnell, MD  
Search results:  2  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-2 Trials Jump to page:

COH Protocol Number: 14044 Number: NCT02014558

Principal Investigator: Margaret O'Donnell, MD
Sponsor: Industrial

Title:  A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

COH Protocol Number: 13395 Number: NCT01925131

Principal Investigator: Margaret O'Donnell, MD
Sponsor: Cooperative Group

Title:  SWOG S1312: A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt’s Leukemia)

Results per page: 25 50 100 All 1-2 Trials Jump to page:

NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.